Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00216762 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Rituximab (Rituxan®) in Chronic Urticaria
A Phase 1 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00216762: Clinical Trial Phase 1 study, sponsored by Johns Hopkins University.
NCT00216762 is a Phase 1 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00216762, a Phase 1 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is being done to find out if a drug called Rituxan (Rituximab) is safe and effective in treating people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.
Interventions
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00216762
The ClinicalTrials.gov registry entry for NCT00216762 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT00216762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00216762 about?
NCT00216762 is a clinical study titled "Safety Study of Rituximab (Rituxan®) in Chronic Urticaria". This study is being done to find out if a drug called Rituxan (Rituximab) is safe and effective in treating people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.
What is the current status of trial NCT00216762?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2006-01. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00216762?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00216762?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.